<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026090</url>
  </required_header>
  <id_info>
    <org_study_id>DRONE_L_04742</org_study_id>
    <nct_id>NCT01026090</nct_id>
  </id_info>
  <brief_title>Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion (ELECTRA)</brief_title>
  <official_title>A Phase IV, Double-blind, Placebo-controlled, Canadian Multicentre Study Comparing Two Treatment Strategies of Dronedarone Administration Following ELECTive caRdioversion for Prevention of Symptomatic Atrial Fibrillation (AF) Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To determine whether daily administration of dronedarone started 5-7 days before
      cardioversion is superior to dronedarone started only after cardioversion with respect to the
      absence of symptomatic, ECG confirmed, atrial fibrillation (AF) recurrence over 6 months in
      adult patients with persistent AF, for whom cardioversion is clinically indicated and planned
      to reduce symptoms and antiarrhythmic treatment is clinically indicated to reduce the risk of
      cardiovascular hospitalization due to AF.

      Secondary Objectives:

      Main Secondary :

        -  To assess the number of symptomatic AF recurrences/patient/6 months with and without ECG
           confirmation;

        -  To assess characteristics of symptomatic AF recurrence in the two treatment arms
           (frequency, duration of episodes, type, number, and severity of AF symptoms per
           patient);

        -  To compare the rates of early recurrences of AF between the two treatment strategies;

      Other secondary:

        -  To assess whether there is a difference in proportion of patients with symptomatic AF
           recurrences (with and without ECG confirmation) between the two treatment strategies;

        -  To assess whether there is a difference in number of electrical cardioversions per
           patient between the two treatment strategies;

        -  To assess the impact of the two strategies on number of shocks, cumulative amount of
           energy delivered, shock failure, and immediate success of cardioversion;

        -  To assess whether there is a difference in rate of cardiovascular (CV) hospitalizations
           and length of hospital stay between the two treatment strategies;

        -  To assess whether there is a difference in quality of life between the two treatment
           strategies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study period of approximatively 6 months consisted in:

        -  Double-blind treatment period (placebo or dronedarone) for 5-7 days prior to
           cardioversion;

        -  Electrical cardioversion;

        -  Open-label treatment period with dronedarone for 6 months after cardioversion.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    'Sponsor decision following recruitment issues, not related to any safety concerns in the study
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with at least one symptomatic, ECG confirmed, AF recurrence</measure>
    <time_frame>6 months from initial cardioversion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Symptomatic AF Recurrences/Patient/6 Months (With or Without ECG Confirmation)</measure>
    <time_frame>up to 6 months from initial cardioversion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of Symptomatic AF Recurrence (Frequency, Duration of Episodes, Type, Number, and Severity of AF Symptoms)</measure>
    <time_frame>up to 6 months from initial cardioversion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Early Recurrence of AF (i.e. From 5 Minutes to to 7 Days Following Cardioversion)</measure>
    <time_frame>up to 7 days following initial cardioversion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Symptomatic AF Recurrences (With or Without ECG Confirmation)</measure>
    <time_frame>up to 6 months from initial cardioversion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Electrical Cardioversions Per Patient</measure>
    <time_frame>up to 6 months from intial cardioversion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Shocks Required During Initial Cardioversion</measure>
    <time_frame>during the initial cardioversion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Amount of Energy Delivered and Shock Failure</measure>
    <time_frame>during the initial cardioversion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Immediate Recurrence of AF (From 5 Seconds to 5 Minutes After Electrical Shock)</measure>
    <time_frame>during the initial cardioversion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CV Hospitalizations</measure>
    <time_frame>up to 6 months from initial cardioversion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life, as Measured by Atrial Fibrillation Severity Scale (AFSS) and Atrial Fibrillation Effect on Quality of Life (AFEQT) Questionnaires</measure>
    <time_frame>Baseline and 6 months after initial cardioversion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">292</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Dronedarone pre-cardioversion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dronedarone 400 mg twice a day for 5-7 days prior to cardioversion, then dronedarone 400 mg twice a day for 6 months after cardioversion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo pre-cardioversion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for dronedarone) twice a day for 5-7 days prior to cardioversion, then dronedarone 400 mg twice a day for 6 months after cardioversion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronedarone</intervention_name>
    <description>Film-coated tablet
Oral administration under fed conditions (during breakfast and dinner)</description>
    <arm_group_label>Dronedarone pre-cardioversion</arm_group_label>
    <arm_group_label>Placebo pre-cardioversion</arm_group_label>
    <other_name>MULTAQ</other_name>
    <other_name>SR33589</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for dronedarone)</intervention_name>
    <description>film-coated tablet strictly identical in appearance
Oral administration under fed conditions (during breakfast and dinner)</description>
    <arm_group_label>Placebo pre-cardioversion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        - Adult patients with persistent AF (current episode at the screening visit &gt;72 hrs and &lt;12
        month duration), for whom cardioversion was clinically indicated and planned to reduce
        symptoms and antiarrhythmic treatment was clinically indicated to reduce the risk of
        cardiovascular hospitalization due to AF.

        Exclusion criteria:

          -  Severe congestive heart failure (NYHA Class IV) and other unstable hemodynamic
             conditions;

          -  Bradycardia &lt;50 bpm;

          -  QTc Bazett interval ≥500 ms;

          -  Second- or third- degree atrio-ventricular (AV) block, or sick sinus syndrome (except
             when used in conjunction with a functioning pacemaker);

          -  Severe hepatic impairment;

          -  Pregnancy and lactation;

          -  History of hypersensitivity reactions to dronedarone or any of its excipients or
             component of the container.

        Concomitant drugs:

          -  Antiarrhythmic drugs (AADs) other than dronedarone should not be administered during
             the study and should be withdrawn for at least five plasma half-lives prior to the
             first study drug administration;

          -  Dronedarone should not be co-administered with strong CYP3A4 inhibitors;

          -  Dronedarone should not be co-administered with drugs inducing torsades de pointes.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 1240033</name>
      <address>
        <city>Abbotsford</city>
        <zip>V2S3N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240026</name>
      <address>
        <city>Barrie</city>
        <zip>L4M4S5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240050</name>
      <address>
        <city>Calgary</city>
        <zip>T2E7C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240010</name>
      <address>
        <city>Cambridge</city>
        <zip>N1R6V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240049</name>
      <address>
        <city>Edmonton</city>
        <zip>T5H4B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240005</name>
      <address>
        <city>Granby</city>
        <zip>J2G1T7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240001</name>
      <address>
        <city>Greenfield Park</city>
        <zip>J4V2G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240046</name>
      <address>
        <city>Grimsby</city>
        <zip>L3M 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240040</name>
      <address>
        <city>Hamilton</city>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240037</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240044</name>
      <address>
        <city>Kingston</city>
        <zip>K7L2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240029</name>
      <address>
        <city>Kitchener</city>
        <zip>N2N2A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240013</name>
      <address>
        <city>Laval</city>
        <zip>H7S2M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240043</name>
      <address>
        <city>Levis</city>
        <zip>G6V3Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240038</name>
      <address>
        <city>Maple Ridge</city>
        <zip>V2X5Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240023</name>
      <address>
        <city>Montreal</city>
        <zip>H1T1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240006</name>
      <address>
        <city>Montreal</city>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240008</name>
      <address>
        <city>Montreal</city>
        <zip>H4J1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240018</name>
      <address>
        <city>Newmarket</city>
        <zip>L3Y8C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240012</name>
      <address>
        <city>Niagara Falls</city>
        <zip>L2E7H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240020</name>
      <address>
        <city>North York</city>
        <zip>M2J1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240015</name>
      <address>
        <city>Oshawa</city>
        <zip>L1J2J9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240036</name>
      <address>
        <city>Oshawa</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240024</name>
      <address>
        <city>Ottawa</city>
        <zip>K1Y4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240032</name>
      <address>
        <city>Ottawa</city>
        <zip>K2G3M8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240056</name>
      <address>
        <city>Red Deer</city>
        <zip>T4N4E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240053</name>
      <address>
        <city>Saskatoon</city>
        <zip>S7N0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240016</name>
      <address>
        <city>Scarborough</city>
        <zip>M1E5E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240027</name>
      <address>
        <city>Sherbrooke</city>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240003</name>
      <address>
        <city>St-Charles Borromee</city>
        <zip>J6E6J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240007</name>
      <address>
        <city>St-Georges</city>
        <zip>G5Y 4T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240041</name>
      <address>
        <city>St. John</city>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240002</name>
      <address>
        <city>Ste-Foy</city>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240021</name>
      <address>
        <city>Sudbury</city>
        <zip>P3C5K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240039</name>
      <address>
        <city>Sudbury</city>
        <zip>P3E2N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240025</name>
      <address>
        <city>Toronto</city>
        <zip>M4N3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240011</name>
      <address>
        <city>Toronto</city>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240019</name>
      <address>
        <city>Toronto</city>
        <zip>M5G2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240009</name>
      <address>
        <city>Trois-Rivières</city>
        <zip>G8Z 4K4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240047</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z1M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240035</name>
      <address>
        <city>Victoria</city>
        <zip>V8R4R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240014</name>
      <address>
        <city>Willowdale</city>
        <zip>M2K2W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240051</name>
      <address>
        <city>Windsor</city>
        <zip>N8X3N9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2009</study_first_submitted>
  <study_first_submitted_qc>December 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <last_update_submitted>August 5, 2014</last_update_submitted>
  <last_update_submitted_qc>August 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

